secwatch.observer — SEC 8-K summary
======================================

Issuer:     Milestone Pharmaceuticals Inc. (MIST)
CIK:        0001408443
Form:       8-K
Filed at:   2022-08-10T23:59:59+00:00
Accession:  0001104659-22-088661
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Milestone Pharma: Phase 3 RAPID PSVT trial reaches 180 events; topline data on track for mid-H2 2022
--------------------------------------------------------------------------------

- Q2 2022 operating loss $16.8M vs income $0.7M prior year due to $15M one-time revenue from Ji Xing in 2021; cash $86.2M.
- RAPID Phase 3 PSVT trial achieved target of 180 confirmed events; topline data expected mid-second half 2022.
- Ji Xing enrolled first patient in Phase 3 etripamil study in China; data may support NDA in China.
- NODE-302 open-label extension data showed 60.2% PSVT conversion at 30 min; 8.5% ED intervention rate.
- R&D expense $10.7M in Q2 2022, up from $9.4M due to RAPID trial advancement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1408443/000110465922088661/0001104659-22-088661-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1408443/000110465922088661/tm2223120d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-088661

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer